Cartesian Therapeutics logo
Cartesian Therapeutics
RNAC | NASDAQ
Chart Builder DCF Calculator
$6.08
-$0.27 (-4.25%)
At close: Nov 16, 2026, 4:00 PM ET
$6.19
+$0.11 (+1.81%)
After-hours: Nov 16, 2026, 7:32 PM ET

Cartesian Therapeutics Company Profile

Company profile explained

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Key Executives

Name Position
Carsten Brunn President, Chief Executive Officer & Chairman of the Board
Blaine T. Davis Chief Financial Officer
Emily English Chief Operating Officer
June Seymour Chief Accounting Officer
Matthew Bartholomae General Counsel & Secretary
Peter G. Traber Head of R&D

Latest SEC Filings

Date Type Title
Sep 29, 2026 8-K Current Report
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 22, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 17, 2026 8-K Current Report
Jun 09, 2026 8-K Current Report
May 26, 2026 8-K Current Report
May 06, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Apr 30, 2026 S-8 Filing
View All SEC Filings ➞
Cartesian Therapeutics
Cartesian Therapeutics logo
Country United States
IPO Date Jun 22, 2016
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Carsten Brunn

Contact Details

7495 New Horizon Way Frederick, Maryland 21703 United States

Stock Details

Ticker Symbol RNAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001453687
CUSIP Number 816212302
ISIN Number US8162123025
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.